Immunotherapy as a neoadjuvant preoperative treatment for locally advanced pulmonary sarcomatoid carcinoma: a case report of clinical efficacy
For patients with locally advanced PSC who do not have significant genetic mutations, the use of immunotherapy as a first-line neoadjuvant and adjuvant therapy may hold promise for achieving a pCR. Further research into this treatment protocol is warranted.
Authors
- Ruilian Chen
- Jiayan Huang (ORCID: https://orcid.org/0000-0003-4166-6119)
- Hanhan Li (ORCID: https://orcid.org/0000-0002-6844-7314)
- Wei Guo (ORCID: https://orcid.org/0000-0002-9924-638X)
- Hanrui Chen (ORCID: https://orcid.org/0000-0002-0058-6609)
- Shang Xiang (ORCID: https://orcid.org/0000-0003-3420-4477)
Institutions
- Guangzhou University of Chinese Medicine (CN)
- First Affiliated Hospital of Guangzhou University of Chinese Medicine (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-01-29
- DOI
- https://doi.org/10.3389/fonc.2025.1483766
- Citations
- 1
- Primary Topic
- Metastasis and carcinoma case studies
- Type
- article
- Field-Weighted Citation Impact
- 1.52
Funders
- National Natural Science Foundation of China
- Natural Science Foundation of Guangdong Province
- Department of Education of Guangdong Province
- Guangzhou University of Chinese Medicine
- Guangzhou University
- Guangzhou Municipal Science and Technology Bureau